DOCSLIB.ORG

Chemoprophylaxis and Intermittent Treatment for Preventing Malaria in Children (Review)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chemoprophylaxis and Intermittent Treatment for Preventing Malaria in Children (Review) Chemoprophylaxis and intermittent treatment for preventing malaria in children (Review) Meremikwu MM, Donegan S, Esu E This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com Chemoprophylaxis and intermittent treatment for preventing malaria in children (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 14 CHARACTERISTICSOFSTUDIES . 20 DATAANDANALYSES. 42 Analysis 1.1. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 1 Clinical malaria..................................... 45 Analysis 1.2. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 2 Severe anaemia. ................................... 47 Analysis 1.3. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 3 Death from anycause.................................... 48 Analysis 1.4. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 4 Hospital admissionforanycause. 49 Analysis 1.5. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 5 Parasitaemia. .................................. 50 Analysis 1.6. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 6 Enlarged spleen. .................................... 51 Analysis 1.7. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 7 Impact on routine immunization: adequate protective antibodies. ................. 51 Analysis 2.1. Comparison 2 Antimalarial vs placebo: cluster-randomized trials, Outcome 1 Clinical malaria. 53 Analysis 2.2. Comparison 2 Antimalarial vs placebo: cluster-randomized trials, Outcome 2 Severe anaemia. 53 Analysis 2.3. Comparison 2 Antimalarial vs placebo: cluster-randomized trials, Outcome 3 Death from any cause. 54 Analysis 2.4. Comparison 2 Antimalarial vs placebo: cluster-randomized trials, Outcome 4 Hospital admission for any cause. .................................... 54 Analysis 3.1. Comparison 3 Antimalarial vs placebo: by drug group, Outcome 1 Clinical malaria. 55 Analysis 3.2. Comparison 3 Antimalarial vs placebo: by drug group, Outcome 2 Severe anaemia. 56 Analysis 4.1. Comparison 4 Antimalarial vs placebo: by seasonality, Outcome 1 Clinical malaria. 57 Analysis 4.2. Comparison 4 Antimalarial vs placebo: by seasonality, Outcome 2 Severe anaemia. 58 Analysis 5.1. Comparison 5 Intermittent treatment vs placebo: by presence of anaemia, Outcome 1 Severe anaemia. 60 Analysis 6.1. Comparison 6 Antimalarial vs placebo: adverse events, Outcome 1 Prophylaxis. 61 Analysis 6.2. Comparison 6 Antimalarial vs placebo: adverse events, Outcome 2 Intermittent treatment. 61 Analysis 7.1. Comparison 7 Antimalarial vs placebo: adequately concealed trials, Outcome 1 Clinical malaria. 62 Analysis 7.2. Comparison 7 Antimalarial vs placebo: adequately concealed trials, Outcome 2 Severe anaemia. 63 Analysis 7.3. Comparison 7 Antimalarial vs placebo: adequately concealed trials, Outcome 3 Death from any cause. 64 Analysis 8.1. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 1 Clinical malaria (relativerisk)................................... 65 Analysis 8.2. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 2 Clinical malaria (incidencerateratio). 65 Analysis 8.3. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 3 Severe anaemia (relativerisk)................................... 66 Analysis 8.4. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 4 Severe anaemia (incidencerateratio). 66 Chemoprophylaxis and intermittent treatment for preventing malaria in children (Review) i Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 8.5. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 5 Death from any cause (relativerisk)................................... 67 Analysis 8.6. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 6 Death from any cause (incidencerateratio). 67 Analysis 8.7. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 7 Impact on routine immunization: adequate protective antibody. ........... 68 APPENDICES ..................................... 68 WHAT’SNEW..................................... 75 HISTORY....................................... 75 CONTRIBUTIONSOFAUTHORS . 76 DECLARATIONSOFINTEREST . 76 SOURCESOFSUPPORT . 76 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 76 INDEXTERMS .................................... 76 Chemoprophylaxis and intermittent treatment for preventing malaria in children (Review) ii Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Chemoprophylaxis and intermittent treatment for preventing malaria in children Martin M Meremikwu1, Sarah Donegan2, Ekpereonne Esu3 1Department of Paediatrics, University of Calabar Teaching Hospital, Calabar, Nigeria. 2International Health Group, Liverpool School of Tropical Medicine, Liverpool, UK. 3Effective Health Care Research Programme - Nigeria, University of Calabar Teaching Hospital, Calabar, Nigeria Contact address: Martin M Meremikwu, Department of Paediatrics, University of Calabar Teaching Hospital, PMB 1115, Calabar, Cross River State, Nigeria. [email protected]. Editorial group: Cochrane Infectious Diseases Group. Publication status and date: Edited (no change to conclusions), published in Issue 1, 2009. Review content assessed as up-to-date: 14 November 2007. Citation: Meremikwu MM, Donegan S, Esu E. Chemoprophylaxis and intermittent treatment for preventing malaria in children. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD003756. DOI: 10.1002/14651858.CD003756.pub3. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ABSTRACT Background Malaria causes repeated illness in children living in endemic areas. Policies of giving antimalarial drugs at regular intervals (prophylaxis or intermittent treatment) are being considered for preschool children. Objectives To evaluate prophylaxis and intermittent treatment with antimalarial drugs to prevent malaria in young children living in malaria- endemic areas. Search strategy We searched the Cochrane Infectious Diseases Group Specialized Register (August 2007), CENTRAL (The Cochrane Library 2007, Issue 3), MEDLINE (1966 to August 2007), EMBASE (1974 to August 2007), LILACS (1982 to August 2007), mRCT (February 2007), and reference lists of identified trials. We also contacted researchers. Selection criteria Individually randomized and cluster-randomized controlled trials comparing antimalarial drugs given at regular intervals (prophylaxis or intermittent treatment) with placebo or no drug in children aged one month to six years or less living in a malaria-endemic area. Data collection and analysis Two authors independently extracted data and assessed the risk of bias in the trials. We used risk ratio (RR) or mean difference with 95% confidence intervals (CI) for meta-analyses. Where we detected heterogeneity and considered it appropriate to combine the trials, we used the random-effects model (REM). Main results Twenty-one trials (19,394 participants), including six cluster-randomized trials, met the inclusion criteria. Prophylaxis or intermittent treatment with antimalarial drugs resulted in fewer clinical malaria episodes (RR 0.53, 95% CI 0.38 to 0.74, REM; 7037 participants, 10 trials), less severe anaemia (RR 0.70, 95% CI 0.52 to 0.94, REM; 5445 participants, 9 trials), and fewer hospital admissions for Chemoprophylaxis and intermittent treatment for preventing malaria in children (Review) 1 Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. any cause (RR 0.64, 95% CI 0.49 to 0.82; 3722 participants, 5 trials). We did not detect a difference in the number of deaths from any cause (RR 0.90, 95% CI 0.65 to 1.23; 7369 participants, 10 trials), but the CI do not exclude a potentially important difference. One trial reported three serious adverse events with no statistically significant difference between study groups (1070 participants). Eight trials measured morbidity and mortality six months to two years after stopping regular antimalarial drugs; overall, there was no statistically significant difference, but participant numbers were small. Authors’ conclusions Prophylaxis and intermittent treatment with antimalarial drugs reduce clinical malaria and severe anaemia in preschool children. PLAIN LANGUAGE SUMMARY Preschool children taking antimalarial drugs regularly are less likely to get malaria or severe anaemia, but more trials are needed to show whether survival is improved Most children in areas where malaria is endemic are semi-immune against serious malaria by the
Load more

Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Antipyretic Measures for Treating Fever in Malaria (Review)
    Antipyretic measures for treating fever in malaria (Review) Meremikwu MM, Logan K, Garner P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com Antipyretic measures for treating fever in malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 2 METHODS ...................................... 2 RESULTS....................................... 3 DISCUSSION ..................................... 5 AUTHORS’CONCLUSIONS . 5 ACKNOWLEDGEMENTS . 5 REFERENCES ..................................... 5 CHARACTERISTICSOFSTUDIES . 6 DATAANDANALYSES. 11 Analysis 1.2. Comparison 1 Antipyretic drugs vs mechanical/no antipyretic, Outcome 2 Maximum temperature fall in 6 hrs. ..................................... 11 Analysis 1.10. Comparison 1 Antipyretic drugs vs mechanical/no antipyretic, Outcome 10 Fever clearance time. 13 Analysis 1.11. Comparison 1 Antipyretic drugs vs mechanical/no antipyretic, Outcome 11 Parasite clearance time. 13 WHAT’SNEW..................................... 13 HISTORY....................................... 14 CONTRIBUTIONSOFAUTHORS . 14 DECLARATIONSOFINTEREST . 14 SOURCESOFSUPPORT . 14 INDEXTERMS ...................................
    [Show full text]
  • Annual Review 2004 Contents Contentsforeword
    Annual Review 2004 Contents ContentsForeword ........................................................................................................................... 3 Editor’s Note ..................................................................................................................... 4 Organization Chart ............................................................................................................ 5 Administrative Board .......................................................................................................... 6 Special Events..................................................................................................................... 8 Consultants ...................................................................................................................... 13 Visiting Professors ............................................................................................................ 13 Faculty Board ...................................................................................................................13 Faculty Senate ..................................................................................................................14 Department of Clinical Tropical Medicine ........................................................................ 15 Department of Helminthology ......................................................................................... 22 Department of Medical Entomology ...............................................................................
    [Show full text]
  • Research for Health Newsletter July-September 2016
    Research for Health Newsletter July-September 2016 A periodic, informative bulletin reporting on the activities of research for health from the office of Knowledge, Bioethics, and Research to inform countries, partners, and PAHO managers and staff on the advances in the execution of PAHO’s Policy on Research for Health. Please send questions and comments to [email protected]. Twitter: @PAHOresearch Find this Newsletter in our Research Portal Thank you The Knowledge Management, Bioethics, and Research (KBR) team appreciates the time dedicated to answer our consumer’s survey in the past Research Newsletter. We truly value the information our respondents provided. SPOTLIGHT 4th Evidence Aid International Conference Evidence Aid is hosting “Humanitarian Evidence”, its fourth in a series of successful international forums on 17 and 18 November 2016 in Washington, D.C. at Georgetown University. The international platform, which addresses the need to deliver time sensitive access to summarized scientific evidence to inform the response and preparation for disasters and humanitarian emergencies, will be hosting the conference alongside Georgetown University, the Uniformed Services University of the Health Sciences (PAHO/WHO). PAHO/WHO worked together on a scientific survey (Policy Delphi Study) that engaged a wide range of key stakeholders in disaster response – the findings inspired this event. Additional information and registration is available on the Evidence Aid website. The event is complemented by a training workshop for emergency respondents to be held at PAHO. More information about the latter under “In the Secretariat” Summer Institute for systematic reviews in nutrition for global policy making Between July 25th and August 5th, experts from Cornell University, the World Health Organization (WHO), the Cochrane Collaboration and the micronutrient Initiative gathered to attend the Summer Institute training for nutrition experts, on developing systematic reviews to inform policies for nutrition and global health.
    [Show full text]
  • Systematic Review of Factors Associated with Quality of Life of Asylum Seekers and Refugees in High-Income Countries Catharina F
    Boor et al. Conflict and Health (2020) 14:48 https://doi.org/10.1186/s13031-020-00292-y REVIEW Open Access Systematic review of factors associated with quality of life of asylum seekers and refugees in high-income countries Catharina F. van der Boor1, Rebekah Amos1, Sarah Nevitt2, Christopher Dowrick1 and Ross G. White1,3* Abstract The stressful experiences that many asylum seekers and refugees (AS&R) are exposed to during forced migration, and during resettlement in host countries, can have a profound impact on their mental health. Comparatively less research attention has been allocated to exploring other indices of quality of life (QoL) in AS&R populations. This review aimed to (i) synthesize the predictors and correlates of QoL of AS&R populations in high-income countries, and (ii) to identify the methodological strengths and weaknesses of this body of research. Fourteen databases were systematically searched (Medline, PsychINFO, CINAHL, Cochrane Library, Health Technology Assessment, National Health Service Economic Evaluation, Educational Resource Index and Abstracts, BiblioMap, Scopus, Social Sciences Citation Index, Evidence Aid, DARE, Web of Science and PubMed). Eligibility criteria included: adults seeking asylum or refuge in a high-income country, primary quantitative data, the use of a measure based on the WHO’s definition of QoL, published in a peer-reviewed journal. A narrative synthesis approach was used, and the quality was assessed using the AXIS tool for cross-sectional studies and the CASP tool for longitudinal studies. Of the 13.656 papers identified, 23 met the eligibility criteria. A wide range of factors were found to have significant associations with QoL.
    [Show full text]
  • Quinoline-Based Hybrid Compounds with Antimalarial Activity
    molecules Review Quinoline-Based Hybrid Compounds with Antimalarial Activity Xhamla Nqoro, Naki Tobeka and Blessing A. Aderibigbe * Department of Chemistry, University of Fort Hare, Alice Campus, Alice 5700, Eastern Cape, South Africa; [email protected] (X.N.); [email protected] (N.T.) * Correspondence: [email protected] Received: 7 November 2017; Accepted: 11 December 2017; Published: 19 December 2017 Abstract: The application of quinoline-based compounds for the treatment of malaria infections is hampered by drug resistance. Drug resistance has led to the combination of quinolines with other classes of antimalarials resulting in enhanced therapeutic outcomes. However, the combination of antimalarials is limited by drug-drug interactions. In order to overcome the aforementioned factors, several researchers have reported hybrid compounds prepared by reacting quinoline-based compounds with other compounds via selected functionalities. This review will focus on the currently reported quinoline-based hybrid compounds and their preclinical studies. Keywords: 4-aminoquinoline; 8-aminoquinoline; malaria; infectious disease; hybrid compound 1. Introduction Malaria is a parasitic infectious disease that is a threat to approximately half of the world’s population. This parasitic disease is transmitted to humans by a female Anopheles mosquito when it takes a blood meal. Pregnant women and young children in the sub-tropical regions are more prone to malaria infection. In 2015, 214 million infections were reported, with approximately 438,000 deaths and the African region accounted for 90% of the deaths [1–3]. Malaria is caused by five parasites of the genus Plasmodium, but the majority of deaths are caused by Plasmodium falciparum and Plasmodium vivax [1,4–6].
    [Show full text]
  • Review of Mass Drug Administration and Primaquine
    Contents Acknowledgements ...................................................................................................................................... 2 Acronyms ...................................................................................................................................................... 3 Introduction .................................................................................................................................................. 4 Methods ....................................................................................................................................................... 4 Findings ......................................................................................................................................................... 6 Study objectives and design ............................................................................................................ 9 Contextual parameters - endemicity, seasonality, target population .......................................... 10 Outcome measures ....................................................................................................................... 13 Drug regimens ............................................................................................................................... 13 Co-Interventions ............................................................................................................................ 15 Delivery methods and community engagement ..........................................................................
    [Show full text]
  • World Health Organization Organisation Mondiale De La
    ORGANISATION MONDIALE DE LA SANTE WORLD HEALTH ORGANIZATION A69/DIV/1 Rev. 1 17 juin 2016 17 June 2016 SOIXANTE-NEUVIEME ASSEMBLEE MONDIALE DE LA SANTE SIXTY-NINTH WORLD HEALTH ASSEMBLY LISTE DES DELEGUES ET AUTRES PARTICIPANTS LIST OF DELEGATES AND OTHER PARTICIPANTS NOTE La liste des délégués et autres participants est établie dans l'ordre alphabétique français. Pour l'ordre alphabétique français, voir l'index à la fin de la liste * * * The list of delegates and other participants is issue in the French alphabetical order. See key for English names at the end of the list. Soixante-Neuvième Assemblée mondiale de la Santé Sixty-ninth World Health Assembly Président : Dr Ahmed Mohammed Al-Saidi (Oman) President Vice- Présidents : Dr S. Subramaniam (Malaysie) Vice-Presidents : Dr Francisco Terrientes (Panama) : Mr Assane Ngueadoum (Tchad) : Dr Ana Isabel Soares (Timor-Leste) : Dr Armen Muradyan (Arménie) Commission A - Committee A Président : Mr Martin Bowles (Australie) Chairman : Vice-Présidents : Ms Taru Koivisto (Finlande) Vice-Chairmen : Mr Nickolas Steel (Grenade) Rapporteur : Ms Aishah Samiya (Maldives) Commission B - Committee B Président : Dr Phusit Prakongsai (Thaîlande) Chairman : Vice-Présidents : Dr Mahlet Kifle (Ethiopie) Vice-Chairmen : Dr Asadi Lari (République islamique d’Iran) Rapporteur : Mr Abdunomon Sidikov (Ouzbekistan) REPRESENTANTS DU CONSEIL EXECUTIF REPRESENTATIVES OF THE EXECUTIVE BOARD Mme Precious Matsoso (Afrique du Sud) Dr Asaad Hafeez (Pakistan) Dr Jeon Man-Bok (République de Corée) -2- Mr Z. Dangor AFGHANISTAN - AFGHANISTAN Adviser to the Deputy Minister, Department of Social Development Professor M. Mendelson Chef de délégation - Chief delegate University of Cape Town Dr F. Feroz Minister of Public Health ALBANIE - ALBANIA Délégué(s) - Delegate(s) Chef de délégation - Chief delegate Dr S.
    [Show full text]
  • Come the Common Challenges Within Conflict Contexts. Conclusion
    Humanitarian Aid s87 standard operating procedures, and recommendations to over- Study/Objective: The aim of the study was to explore and come the common challenges within conflict contexts. describe problems and difficulties in situations with migrants in Conclusion: The outcome document will be used as a refer- emergency care in order to plan for an appropriate and effective ence guide to build on existing knowledge in mobile health teaching program for emergency care providers. service delivery in complex emergencies. Background: In 2016, there were many posed threats to Prehosp Disaster Med 2017;32(Suppl. 1):s86-s87 emergency medicine practitioners all over Europe. Terrorism, doi:10.1017/S1049023X17002266 climate changes, and seasonal diseases could be sufficient to challenge emergency medical systems; they add to the hardships facing the thousands of migrants who continue to cross into Prevention and Risk Management from Nature to Society: Europe with the never-ending conflict in Syria and Iraq. How can Medicine Help Reduce the Refugee Crisis in In those settings, emergency medicine must play its key role of Mexico? being the last resort for people with no primary health care and Joanne Joloy no alternative. Ya Respondiste A.C, Ciudad de México/Mexico Methods: An explorative study was carried out using a sample of 67 emergency care providers, 15 physicians, 52 registered nurses, Study/Objective: To sensitize Mexican doctors on preventing 46 women, and 21 men experienced in emergency care. They immigrant disease complications. documented their experiences of problematic situations. Background: Mexico serves as a halfway point for immigrants Results: The health care professionals’ experiences of problematic seeking safety and a better life.
    [Show full text]
  • Indoor Residual Spraying for Preventing Malaria (Review)
    Indoor residual spraying for preventing malaria (Review) Pluess B, Tanser FC, Lengeler C, Sharp BL This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 4 http://www.thecochranelibrary.com Indoor residual spraying for preventing malaria (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 10 Figure2. ..................................... 11 DISCUSSION ..................................... 18 AUTHORS’CONCLUSIONS . 19 ACKNOWLEDGEMENTS . 19 REFERENCES ..................................... 20 CHARACTERISTICSOFSTUDIES . 27 DATAANDANALYSES. 45 HISTORY....................................... 45 CONTRIBUTIONSOFAUTHORS . 45 DECLARATIONSOFINTEREST . 45 SOURCESOFSUPPORT . 45 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 45 Indoor residual spraying for preventing malaria (Review) i Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Indoor residual spraying for preventing malaria Bianca Pluess1, Frank C Tanser2, Christian Lengeler1, Brian L Sharp3 1Public Health and Epidemiology, Swiss Tropical
    [Show full text]
  • 1 Antimalarial Activity of the 8 - Aminoquinolines Edward A
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln US Army Research U.S. Department of Defense 1991 1 Antimalarial Activity of the 8 - Aminoquinolines Edward A. Nodiff Franklin Research Center, Arvin Calspan Corporation, Valley Forge Corporate Center, Norristown, PA Sankar Chatterjee Department of Medicinal Chemistry, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, DC Hikmat A. Musallam Department of Medicinal Chemistry, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, DC Follow this and additional works at: http://digitalcommons.unl.edu/usarmyresearch Nodiff, Edward A.; Chatterjee, Sankar; and Musallam, Hikmat A., "1 Antimalarial Activity of the 8 - Aminoquinolines" (1991). US Army Research. 337. http://digitalcommons.unl.edu/usarmyresearch/337 This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in US Army Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Progress in Medicinal Chemistry - Vol. 28, edited by G.P. Ellis and G.B. West 0 1991, Elsevier Science Publishers, B.V. 1 Antimalarial Activity of the 8- Aminoquinoline s EDWARD A. NODIFF, B.A. SANKAR CHATTERJEE, Ph.D. and HIKMAT A. MUSALLAM, Ph.D.2 Franklin Research Center, Arvin Calspan Corporation, Valley Forge Corporate Center, 2600 Monroe Boulevard, Norristown, PA 19403 and 'Department of Medicinal Chemistry, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, DC 20307-5100, U.S.A. INTRODUCTION 2 THE PARASITE Exoerythrocytic phase Erythrocytic phase Sporogony THE DISEASE 4 CLASSIFICATION OF ANTIMALARIAL DRUGS 4 HISTORY 5 METHODS FOR ANTIMALARIAL DRUG EVALUATION 8 Rane blood schizontocidal screen (P.
    [Show full text]
  • Pyrimethamine and Proguanil Are the Two Most Widely Used DHFR Inhibitor Antimalarial Drugs. Cycloguanil Is the Active Metabolite of the Proguanil (1,2)
    Jpn. J. Med. Sci. Biol., 49, 1-14, 1996. IN VITRO SELECTION OF PLASMODIUM FALCIPARUM LINES RESISTANT TO DIHYDROFOLATE-REDUCTASE INHIBITORS AND CROSS RESISTANCE STUDIES Virendra K. BHASIN* and Lathika NAIR Department of Zoology, University of Delhi, Delhi 110007, India (Received July 27, 1995. Accepted November 6, 1995) SUMMARY: A cloned Plasmodium falciparum line was subjected to in vitro drug pressure, by employing a relapse protocol, to select progressively resistant falciparum lines to pyrimethamine and cycloguanil, the two dihydrofolate- reductase (DHFR) inhibitor antimalarial drugs. The falciparum lines resistant to pyrimethamine were selected much faster than those resistant to cycloguanil. In 348 days of selection/cultivation, there was 2,400-fold increase in IC50 value to pyrimethamine, whereas only about 75-fold decrease in sensitivity to cycloguanil was registered in 351 days. Pyrimethamine-resistant parasites acquired a degree of cross resistance to cycloguanil and methotrexate, another DHFR inhibitor, but did not show any cross resistance to some other groups of antimalarial drugs. The highly pyrimethamine-resistant line was not predisposed for faster selection to cycloguanil resistance. Resistance acquired to pyrimethamine was stable. The series of resistant lines obtained form a good material to study the •eevolution•f of resistance more meaningfully at molecular level. INTRODUCTION Pyrimethamine and proguanil are the two most widely used DHFR inhibitor antimalarial drugs. Cycloguanil is the active metabolite of the proguanil (1,2). There is abundant evidence to indicate that the pyrimethamine resistance is now widely distributed throughout malaria-endemic areas of the world (3-5). The incidence of the proguanil resistance appears to be in doubt and *To whom correspondence should be addressed .
    [Show full text]